<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106101</url>
  </required_header>
  <id_info>
    <org_study_id>EM-DsD-002</org_study_id>
    <nct_id>NCT05106101</nct_id>
  </id_info>
  <brief_title>L-glutamine Treatment in Patients With Diverticulosis</brief_title>
  <official_title>A Pilot/Phase 1, Interventional, Open-label, Multi-center Study to Assess the Safety and Efficacy of L-glutamine Treatment in Patients With Diverticulosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emmaus Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emmaus Medical, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment&#xD;
      for patients with diverticulosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will undergo a 4 weeks screening period to determine eligibility for study&#xD;
      entry. At Week 0, patients who meet eligibility requirements will be given L-glutamine (15&#xD;
      grams, twice daily)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the number of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis.</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <description>Number of diverticula for both the descending colon and sigmoid will be counted at baseline, at 6 months and at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline the size of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis</measure>
    <time_frame>Baseline, 6 month and 12 months</time_frame>
    <description>Size of diverticula at the descending and sigmoid colon will be estimated as small only, large only, or both small and large, where large is defined as greater than 7 mm in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Hematological Parameters - Hemoglobin</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's hemoglobin will be collected at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Hematological Parameters - Hematocrit</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's hematocrit will be collected at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Vital Signs - Blood Pressure</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's blood pressure will be collected at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's pulse rate will be collected at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Vital Signs - Temperature</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's temperature will be collected at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of oral L-glutamine on Vital Signs - Respiration</measure>
    <time_frame>Baseline to 48 weeks (12 months)</time_frame>
    <description>Patient's respiration will be collected at each visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Diverticulosis, Colonic</condition>
  <arm_group>
    <arm_group_label>L-glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-glutamine</intervention_name>
    <description>L-glutamine oral powder in 5 gram packet</description>
    <arm_group_label>L-glutamine</arm_group_label>
    <other_name>oral L-glutamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥50 years of age.&#xD;
&#xD;
          2. Uncomplicated diverticulosis confirmed by colonoscopy.&#xD;
&#xD;
          3. Colonoscopy indicates ≥5 colonic diverticula (pouches) in the descending/sigmoid colon&#xD;
             and &lt; approximately10 colonic diverticula (pouches) per segment (e.g. proximal&#xD;
             descending, distal descending, proximal sigmoid, and distal sigmoid.)&#xD;
&#xD;
          4. If the patient is a female of child-bearing potential, she agrees to avoid pregnancy&#xD;
             during the study and is willing and agrees to practice a recognized form of birth&#xD;
             control during the course of the study (e.g., barrier, birth control pills, or&#xD;
             abstinence).&#xD;
&#xD;
          5. Patients who have given their free and written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute diverticulitis (both complicated and uncomplicated).&#xD;
&#xD;
          2. Acute colitis&#xD;
&#xD;
          3. History of inflammatory bowel disease, colon resection, polyposis syndrome, severe&#xD;
             strictures, and perforation.&#xD;
&#xD;
          4. Active bleeding&#xD;
&#xD;
          5. More than 40 diverticula&#xD;
&#xD;
          6. Chronic renal insufficiency&#xD;
&#xD;
          7. Chronic liver disease.&#xD;
&#xD;
          8. Patient is pregnant or lactating or has the intention of becoming pregnant during the&#xD;
             study (if female of childbearing potential).&#xD;
&#xD;
          9. Inability to give a valid informed consent or to properly follow the protocol.&#xD;
&#xD;
         10. Patients with an active malignancy of any type, or a recent history of malignancy&#xD;
             within the last 5 years.&#xD;
&#xD;
         11. Treated with an investigational medication/treatment within 30 days prior to the&#xD;
             screening visit.&#xD;
&#xD;
         12. Currently enrolled in an Investigational study&#xD;
&#xD;
         13. Patient is currently taking or has been treated with any form of glutamine supplement&#xD;
             within 30 days of the screening visit.&#xD;
&#xD;
         14. Previous difficulty pulling or passing of scope or difficulty completing colonoscopy.&#xD;
&#xD;
         15. There are factors that would, in the judgment of the investigator, make it difficult&#xD;
             for the patient to comply with the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka L Niihara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emmaus Medical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Lundquist Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diverticulum</mesh_term>
    <mesh_term>Diverticular Diseases</mesh_term>
    <mesh_term>Diverticulosis, Colonic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

